ReviewNature reviews. Nephrology2010
A 'biomarker signature' for tolerance in transplantation.
Review in Nature reviews. Nephrology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A risk assessment model of acute liver allograft rejection by genetic polymorphism of CD276.Molecular genetics & genomic medicine · 2019Article
- Transplantation tolerance: don't forget about the B cells.Clinical and experimental immunology · 2017Review
- Biomarkers in renal transplantation: An updated review.World journal of transplantation · 2017Review
- Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine.Canadian journal of kidney health and disease · 2017Article
- T-cell exhaustion in allograft rejection and tolerance.Current opinion in organ transplantation · 2015Review
- Establishment of a global virtual laboratory for transplantation: a symposium report.Transplantation · 2015Article
- Recipients with in utero induction of tolerance upregulated MHC class I in the engrafted donor skin.Disease markers · 2014Article
- Issues in solid-organ transplantation in children: translational research from bench to bedside.Clinics (Sao Paulo, Brazil) · 2014Review
- T-regulatory cell-mediated immune tolerance as a potential immunotherapeutic strategy to facilitate graft survival.Blood transfusion = Trasfusione del sangue · 2013Review
- Immunologic monitoring in transplantation revisited.Current opinion in organ transplantation · 2012Review
- Memory T cells and their exhaustive differentiation in allograft tolerance and rejection.Current opinion in organ transplantation · 2012Review
- A New-Age for Biologic Therapies: Long-Term Drug-Free Therapy with BiP?Frontiers in immunology · 2012Article
- Identifying biomarkers as diagnostic tools in kidney transplantation.Expert review of molecular diagnostics · 2011Article
- Tolerance: an overview and perspectives.Nature reviews. Nephrology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In the past decade, an explosion in the number of high-throughput tools for the measurement of different cellular products has occurred. These tools have the potential to further our understanding of human disease and this development has facilitated the identification of new biomarkers in all areas of medicine. In the field of solid organ transplantation, two different areas have developed: the use of biomarkers to predict allograft tolerance for the identification of patients who can be weaned from immunosuppressive therapy, and biomarkers for the prediction of allograft rejection, so that parenchymal damage can be prevented before it becomes irreversible. In this Review, we discuss the development of biomarkers that are indicative of transplant tolerance. Identifying patients in whom donor-specific tolerance has developed would constitute a major advance in the care of organ transplant recipients. This ability would allow the minimization or even the withdrawal of immunosuppressive therapy in selected patients, thus reducing the number of adverse effects and costs, and optimizing long-term graft outcomes. The routine clinical use of these biomarkers, once validated, would bring to the fore the possibility of personalized medicine.
Indexed as
Identifiers
20717098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.